Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

Experts in multiple sclerosis discuss overall patient satisfaction with current disease-modifying therapies for multiple sclerosis, highlighting the need for more therapies that stave off decline and disease progression.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

Now Viewing

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

EP: 13.Multiple Sclerosis: Looking Toward the Future

1. How is patient satisfaction overall with current disease modifying therapies for MS?

Related Videos

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

Related Content

Advertisement

April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick

Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.

April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.